Imfinzi and sasanlimab look nearly identical, but it’s a different story for Roche’s Tecentriq.

The company reveals the first overall survival data in adjuvant ER-positive breast cancer.

Boehringer’s Hernexeos and Bayer’s sevabertinib look similar in first-line HER2-mutant NSCLC.

First data with Astra’s torvutatug samrotecan come as Lilly unveils its first folate pivotal trial.

The ESMO regular abstract lift reveals first human datasets for several projects.

Data with the T-cell engager ASP2138 look lukewarm, but could improve with combos.

The group toplines a phase 2 win with Alphamedix.

Datroway succeeds on PFS and OS in Tropion-Breast02, and an ESMO showdown beckons.

The first pivotal data with raludotatug deruxtecan will feature as a late-breaker.